Companion Animal Tablet Compression, Coating, and Dissolution Boundary

Wet granulation is the default route for enrofloxacin tablet strengths from 22.7 mg to 272 mg per unit because low-dose direct compression blends containing 5–30% w/w enrofloxacin base show segregation across hopper discharge cycles on rotary presses operating above 45 rpm. The dosage form is released against Ph. Eur. 0478, Ph. Eur. 2.9.1, Ph. Eur. 2.9.3, Ph. Eur. 2.9.40, USP <905>, and VICH GL18. The formulation addition ratio is calculated on dried-substance assay, with the base equivalent corrected by the batch assay value and a 2–5% overage; for a 250–650 mg core weight the API is commonly 10–35% w/w. The downstream production path includes screening the API through a 0.5 mm sieve, high-shear wet granulation with a 5% povidone K30 binder solution, wet milling through a 1.0–1.5 mm screen, fluid-bed drying at inlet air 50–60°C to loss on drying 1.5–2.5%, blending with crospovidone and sodium starch glycolate, lubrication with 0.5–0.75% w/w magnesium stearate for 3–5 min, and compression to hardness 60–100 N with friability ≤0.8%. Film coating with light-protective hydroxypropyl methylcellulose is applied when the primary package does not provide total UV barrier. Dissolution is run in 900 mL of 0.1 M hydrochloric acid at 37±0.5°C using USP apparatus II at 75 rpm; failure to reach Q=80% at 30 min on a routine lot is traceable to over-dried granulate or excess lubricant. Terminal product is a round, scored, film-coated veterinary tablet for oral administration to dogs and cats.

In poultry house medication, drinking water application of enrofloxacin is formulated as a water-soluble granule, not as a plain powder blend, because direct powder mixes stratify during storage and produce variable recovered concentrations under field conditions. The granule formulation is controlled under Ph. Eur. 0499 and Ph. Eur. 2.9.12 sieve test, with residual solvent testing aligned to VICH GL18. Enrofloxacin base is incorporated at 5–20% w/w, with 10% w/w being the most common loading; lactose monohydrate, povidone K30, and anhydrous sodium carbonate are used to maintain rapid alkaline dissolution. The batch is wet-massed, extruded through a 0.8 mm screen, spheronised, and dried at 40–50°C to final moisture ≤2.0%. The downstream production target is complete solubility within 3–5 min in tap water at 15–25°C; water hardness above 300 mg/L CaCO₃ and dissolved iron above 0.3 mg/L depress recovered enrofloxacin concentration and require acidification to pH 4.0–5.5 or a chelating agent in the water system. The final drinking water dose is 50 mg/L for a 10 mg/kg body weight daily dose at a water intake of 0.2 L/kg, with the solution consumed over 4–6 h and protected from ultraviolet exposure. Terminal product is an aluminum-sachet-packed veterinary water-soluble granule for poultry flocks, with each sachet pre-dosed for a measured water line volume.

What Limits Sterile Filtration Throughput in Alkaline 100 mg/mL Injectables?

A 100 mg/mL enrofloxacin injectable solution intended for cattle and swine is manufactured as an alkaline aqueous system because enrofloxacin solubility increases sharply above pH 9.5; the finished solution is adjusted to pH 9.8–10.4 with sodium hydroxide, and carbon dioxide ingress during holding must be avoided because carbonate precipitation can reduce filter throughput and visible-particle pass rate. The compliance package includes Ph. Eur. 0520, Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, USP <1>, and USP <85>. The API addition ratio is 10% w/v as enrofloxacin base equivalent, adjusted by assay and moisture; if enrofloxacin hydrochloride is used, the base-equivalent correction factor is applied before pH adjustment. The downstream production sequence includes dissolution in WFI at 20–30°C, pH adjustment under nitrogen overlay, adsorption-stage filtration through 0.45 µm and sterilising filtration through 0.22 µm PVDF or PES membranes, and aseptic filling into amber glass vials under Grade A conditions. The solution is light-sensitive; hold times in stainless steel tanks without UV shielding are limited to the validated period established for the specific formulation, and filter compatibility with the alkaline vehicle is confirmed before scale-up. Terminal autoclaving is generally avoided in this alkaline presentation because pH drift and closure-crimp stress under saturated steam may produce low-level precipitate. Terminal product is a sterile injectable solution containing 100 mg/mL enrofloxacin for subcutaneous or intramuscular use in food-producing species, with vial sizes from 50 mL to 250 mL.

Where finfish medication is authorised, enrofloxacin medicated feed premixes are controlled under Ph. Eur. 1037 and homogenised to a coefficient of variation ≤5% using a double-ribbon or ploughshare mixer with total batch times of 12–20 min. The premix addition ratio is typically 10% w/w enrofloxacin base on a lactose or wheat bran carrier, with silicon dioxide at 0.5–1.0% w/w for flow and moisture control; the subsequent feed incorporation target is 1.5–3.0 g enrofloxacin per kg finished feed, equivalent to a 1.5–3.0% w/w inclusion of a 10% premix. Downstream production for extruded fish feed requires the premix to be applied after extrusion and drying when pellet core temperature exceeds 70°C, because high-temperature extrusion above this threshold introduces assay variability; vacuum coating or post-pelleting liquid spraying onto 0.4–0.8 mm micropellets is preferred, with the medicated oil layer stabilised by the feed mill before bagging. Published forced-degradation data for this specific premix-in-feed configuration is limited; therefore, mill-scale homogeneity testing must be repeated for each new carrier lot and feed matrix. Terminal product is a medicated finfish feed or top-dressed premix for oral administration during bacterial disease episodes, with the treated feed held out of direct sunlight and used within the veterinarian-specified treatment window.

When Neonatal Piglet Dosing Uses Oral Liquid Dispersions Instead of Feed Premix

When neonatal piglets cannot be reliably dosed via medicated feed, an oral liquid presentation is selected because dosing volume can be adapted to body weight at the pen level without requiring feed intake. The oral liquid is controlled under Ph. Eur. 0672 and Ph. Eur. 2.9.5, with VICH GL18 applied to residual solvent limits. Enrofloxacin is added at 10% w/v or 20% w/v base equivalent, depending on the dosing device and target species; the vehicle is purified water adjusted to pH 9.5–10.5 with sodium hydroxide, and a preservative-free or benzyl alcohol-containing formulation is selected based on the authorised target species. The production path includes dissolution at 25–35°C, filtration through 5 µm cartridge depth media to remove undissolved carbonate particles, and filling into amber PET bottles with tamper-evident closures. The product must remain clear at 15–25°C; storage below 10°C can produce temporary precipitation that redissolves after warming, but repeated thermal cycling is not recommended. Terminal product is an oral liquid or dispersion for piglet and calf administration via drench or dosing pump, with withdrawal periods determined by regional residue regulations.

Capsule Fill Weight, Powder Flow, and Light Protection in Companion Animal Regimens

Hard gelatin capsule lines for enrofloxacin are configured when the veterinarian requires dose adjustment across body-weight bands that cannot be met by fixed tablet strengths. The capsule formulation is controlled under Ph. Eur. 0016 and Ph. Eur. 2.9.1, with USP <711> dissolution used for routine release. Enrofloxacin base is incorporated at 10–25% w/w of the filled powder mixture for low-dose capsules of 22.7 mg to 68 mg, with lactose or microcrystalline cellulose as filler, sodium starch glycolate at 2–4% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w. The downstream production process is direct filling after sieving through 0.5 mm mesh, with fill weight monitored to ±3% capsule-to-capsule variation on automatic tamping machines; powder flow above 0.4 g/s through a 4 mm orifice is targeted to maintain fill weight uniformity. The capsule shells are coloured with titanium dioxide or iron oxide to reduce light transmission, and the finished product is packed in PVC/aluminium blisters. Terminal product is a hard gelatin capsule for oral administration to dogs and cats, with dose strengths prepared from the same validated master blend to minimise cross-contamination risk in multi-product facilities.